NASDAQ:EKSO - Nasdaq - US2826443010 - Common Stock - Currency: USD
0.302
0 (-0.23%)
The current stock price of EKSO is 0.302 USD. In the past month the price decreased by -37.58%. In the past year, price decreased by -73.74%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.95 | 232.41B | ||
ISRG | INTUITIVE SURGICAL INC | 72.3 | 197.97B | ||
BSX | BOSTON SCIENTIFIC CORP | 38.99 | 155.73B | ||
SYK | STRYKER CORP | 30.54 | 146.23B | ||
MDT | MEDTRONIC PLC | 15.09 | 106.43B | ||
BDX | BECTON DICKINSON AND CO | 12.25 | 49.47B | ||
EW | EDWARDS LIFESCIENCES CORP | 30.08 | 45.88B | ||
IDXX | IDEXX LABORATORIES INC | 45.03 | 41.60B | ||
RMD | RESMED INC | 26.96 | 35.89B | ||
DXCM | DEXCOM INC | 52 | 33.64B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.33 | 32.30B | ||
STE | STERIS PLC | 26.25 | 24.09B |
Ekso Bionics Holdings, Inc. engages in the design, development and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company is headquartered in San Rafael California, California and currently employs 61 full-time employees. The company went IPO on 2013-04-10. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. The company operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.
EKSO BIONICS HOLDINGS INC
101 Glacier Point, Suite A
San Rafael California CALIFORNIA 94804 US
CEO: Jack Peurach
Employees: 64
Phone: 15109841761
The current stock price of EKSO is 0.302 USD. The price decreased by -0.23% in the last trading session.
The exchange symbol of EKSO BIONICS HOLDINGS INC is EKSO and it is listed on the Nasdaq exchange.
EKSO stock is listed on the Nasdaq exchange.
8 analysts have analysed EKSO and the average price target is 5.1 USD. This implies a price increase of 1588.74% is expected in the next year compared to the current price of 0.302. Check the EKSO BIONICS HOLDINGS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
EKSO BIONICS HOLDINGS INC (EKSO) has a market capitalization of 8.77M USD. This makes EKSO a Nano Cap stock.
EKSO BIONICS HOLDINGS INC (EKSO) currently has 64 employees.
EKSO BIONICS HOLDINGS INC (EKSO) has a resistance level at 0.36. Check the full technical report for a detailed analysis of EKSO support and resistance levels.
The Revenue of EKSO BIONICS HOLDINGS INC (EKSO) is expected to decline by -1.46% in the next year. Check the estimates tab for more information on the EKSO EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
EKSO does not pay a dividend.
EKSO BIONICS HOLDINGS INC (EKSO) will report earnings on 2025-07-28, after the market close.
EKSO BIONICS HOLDINGS INC (EKSO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.49).
The outstanding short interest for EKSO BIONICS HOLDINGS INC (EKSO) is 1.22% of its float. Check the ownership tab for more information on the EKSO short interest.
ChartMill assigns a fundamental rating of 2 / 10 to EKSO. EKSO may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months EKSO reported a non-GAAP Earnings per Share(EPS) of -0.49. The EPS increased by 49.48% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -39.52% | ||
ROE | -85.03% | ||
Debt/Equity | 0.28 |
ChartMill assigns a Buy % Consensus number of 83% to EKSO. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 35.58% and a revenue growth -1.46% for EKSO